Zydus receives Phase I clinical trial permission for ZYBKZ
From Drug Controller General of India
Zydus Cadila announced that it has received an approval from the Drug Controller General of India (DCGI) to initiate Phase I clinical trials for its Investigational New Drug (IND) ZYBK2, a New Chemical Entity (NCE) intended to treat Rheumatoid Arthritis (RA).Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content